The importance of cell line authentication has been well recognized by the research community, and recently a list of 360 crosscontaminated and misidentified cell lines has been published, to be updated when necessary. 1 At present the widely proposed technology for human cell line authentication is DNA genotyping by short tandem repeat (STR) -PCR, and the standard method for analyzing STR fragments (ie, fragment length analysis [FLA] ) is capillary electrophoresis. 2 -5 There are a number of commercially available STR kits commonly used that provide convenient multiplex PCR amplification of the markers. 4 The downstream FLA is, however, normally done by capillary electrophoresis, which requires state-of-the-art facilities and properly trained specialists to analyze the data obtained, resulting in outsourcing of the cell authentication service for the majority of research laboratories. We were interested in exploring the possibility of using other electrophoresis platforms for FLA, such as the Agilent 2100 Bioanalyzer, which is a microfluidics-based Lab-on-Chip system for sizing and quantification of DNA, RNA, proteins, and cells. 6 -9 It also provides quality control of DNA, RNA, and protein samples in a broad range of molecular assays. 10 -12 Recently the Bioanalyzer has been employed to resolve STR fragments in forensic samples as well as to identify fish species based on their restriction fragment length polymorphism pattern. 13, 14 Our Cellular and Molecular Neuro-oncology Research Laboratories at the University of Portsmouth act as the brain tumor cell culture repository for the South of England Brain Tumour Alliance (SEBTA), a network formed in 2011 by 7 regional centers in the south of England that are involved in diagnosis, treatment, and research in neuro-oncology (http://sebta.org). With its clearly identified strategic aims, SEBTA promotes and facilitates increased collaboration among those centers, including sharing valuable tissues and cell lines. Therefore, apart from our own group, we are responsible for the authentication of cell lines that are distributed across the SEBTA centers by our brain tumor cell culture repository, and it is critical for us to establish an efficient workflow for the routine cell authentication tests. For that purpose, in the present study we investigated the potential of this microfluidic system in STR genotyping of human brain tumor cell lines, exploiting its capacity for DNA fragment separating and sizing. The microfluidics-based electrophoresis proved to be an effective and simple method for FLA in replacement of capillary electrophoresis. In addition, it created accurate and reproducible DNA profiling data for the cell lines studied, offering an efficient and reliable tool for our routine cell line genotyping test.
Materials and Methods

Cell Lines
All primary cell lines were derived from patient biopsy materials under ethics permissions LREC 00-173, KCH 11-094, or 11/SC/ 0048 in accordance with the National Research Ethics Service. These cell lines in addition to 4 established commercially available cell lines were used in the first part of the DNA profiling studies. The primary glioma cell lines included a grade II astrocytoma UP-016/ Passage (P)2, a grade III astrocytoma UP-032 (P5), and 3 grade IV glioblastoma multiforme (GBM) cell lines: IN699 (P17), UP-019 (P9), and UP-029 (P5). One primary lung brain metastatic cell line, UP-024 (P4), was also included in this study. Commercially available cell lines analyzed were: the GBM cell line SNB-19 (German Collection of Microorganisms and Cell Cultures [DSMZ]; P63), the human lung carcinoma cell line NCI-H1299 (American Type Culture Collection [ATCC]; P25), the rhabdomyosarcoma cell line TE-671 (ATCC; P22), and the normal human astrocyte cell line CC2565 (Lonza Biologics; P10). Cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Invitrogen) with 10% fetal calf serum (FCS; Sigma-Aldrich), with the exception of NCI-H1299 cells that were cultured in Roswell Park Memorial Institute 1640 medium (Sigma-Aldrich).
To monitor potential changes (in particular, crosscontamination) in cell lines over long-term culture, UP-029 and another biopsy-derived GBM cell line, SEBTA-003 (cultured in 10% FCS/DMEM), were genotyped in the second part of these studies. Cells were cultured for 5 continuous passages with a 5-passage interval (ie, P10, P15, P20, P25, and P30 of UP-029; P8, P13, P18, P23, and P28 of SEBTA-003).
Short Tandem Repeat-PCR
Genomic DNA was extracted from cultured cells using the QIAamp DNA Mini Kit (Qiagen). STR-based multiplex PCR was carried out with the StemElite ID System (Promega) according to the manufacturer's protocol. 15 DNA amplification was set up in a final volume of 25 mL reaction, including 1 × Enzyme Mix, 1 × Primer Pair Mix, and 2 ng of template DNA. PCR was performed on the MyCycler Thermal Cycler (Bio-Rad) using the thermal cycling program recommended for the Applied Biosystems GeneAmp PCR System 9600 Thermal Cycler, according to the StemElite ID System Manual (Promega). 15 The step-by-step thermal cycling protocol is as follows-step 1: 968C for 2 min; step 2: 948C for 30 s; step 3 (×10 cycles): ramp 60 s to 608C and hold for 30 s, then ramp 50 s to 708C and hold for 45 s; step 4: 908C for 30 s; step 5 (×22 cycles): ramp 60 s to 608C and hold for 30 s, then ramp 50 s to 708C and hold for 45 s; step 6: 608C for 30 min. The primers of the StemElite ID System Kit amplify 9 human STR loci, including D21S11, TH01, TPOX, vWA, CSF1PO, D16S539, D7S820, D13S317, and D5S818, as well as amelogenin for gender identification. These markers are selected from the set of core STR loci that has been approved by the human identity testing community. 4, 16 STR-PCR was performed in 3 independent experiments for all cell lines in the first part of the studies (experiments 1, 2, and 3), whereas 1 STR-PCR experiment was carried out for 5 continuous passages each of UP-029 and SEBTA-003, in the crosscontamination test study. A negative PCR reaction was included in each of the experiments where template DNA was replaced with water.
Fragment Length Analysis
Amplified alleles in the STR-PCR products were separated on the Agilent 2100 Bioanalyzer with the Agilent DNA 1000 Kit according to the standard protocol with slight modification. 17 In essence, the DNA chip was first primed with 9 mL of the gel-dye mixture, then 3 mL of the PCR product was added to each of the 12 sample wells along with 3 mL of the internal marker (Agilent). One microliter of the Agilent DNA 1000 ladder, used as a sizing standard, was loaded into the ladder well with 5 mL of the internal marker. After electrophoresis, the amplified alleles from each sample were analyzed using the manufacturer's software, 2100 Expert, provided with the instrument; the size of each fragment was determined based on the ladder and internal standards. In addition, the STR markers were identified based on their size ranges. 15 Fragment length analysis was done with the Bioanalyzer for all samples from 3 independent STR-PCR experiments (1, 2, and 3). In comparison, samples from the first experiment (Exp 1) were sent to Eurofins MWG Operon (http://www.eurofinsgenomics.eu) and analyzed using standard procedures of capillary electrophoresis on the Applied Biosystems 3130xl Genetic Analyzer, as described in the service information document (Eurofins MWG Operon). 18 The relevant negative sample was also included in each of the FLA analyses as a control.
Results
DNA Profiling of Cell Lines by Microfluidics-based Electrophoresis and Capillary Electrophoresis
To assess the application of the microfluidics-based electrophoresis method in STR-based DNA profiling of human cell lines, amplified STR fragments of the 10 cell lines from the first experiment (exp 1) were separated and analyzed by both microfluidic and capillary electrophoresis. The former was performed in our laboratory using the Agilent DNA 1000 Kit and the data were analyzed by the Agilent 2100 Expert software, the latter by Eurofins MWG's FLA service using the ABI 3130xl Genetic Analyzer as recommended for the StemElite ID System. 15 Amplified STR fragments from all 10 cell lines were successfully separated by the Bioanalyzer, as demonstrated by the representative electropherograms ( Fig. 1A and B) . Although DNA fragment sizing was on average around 20 bp larger than that obtained from capillary electrophoresis, likely due to the dye-labeled PCR primers that had incorporated into the fragments and consequently reduced the migration speed of those fragments, both sets of data were highly comparable in terms of the DNA profiles of the cell lines studied (Table 1 ). There were An et al.: Brain tumor cell line authentication differences in several of the STR markers when comparing these 2 methods. When the STR marker D21S11 was analyzed, 4 of the 10 cell lines using the microfluidic method failed to detect the heterozygous alleles compared with capillary electrophoresis (shaded cells in Table 1 ). The STR markers D5S818, vWA, TPOX, and CSF1PO showed homozygous alleles in 10% (1/10) of the cell lines where capillary electrophoresis revealed heterozygosity of the associated marker in those cell lines (shaded cells in Table 1 ). On the contrary, the microfluidic system was highly consistent in terms of analyzing homozygous STR markers and the homozygosity matched 100% between those 2 methods (Table 1 ). In one cell line (UP-029), there was a discrepancy in the sizes of 2 alleles of D7S820 between the methods, with a 1-bp difference in the microfluidic method, whereas there was 16 bp by capillary electrophoresis (underlined cells in Table 1 ). In total, 92% (92/ 100) of the analyzed markers showed excellent similarity between the Bioanalyzer and capillary electrophoresis in terms of fragment sizing. Importantly, both microfluidic and capillary electrophoresis revealed a unique DNA profile of each cell line, presented by fragment sizing for the former (Table 1) and by the internationally recognized standard for the latter ( Table 2 ). The DNA profiles of NCI-H1299 and TE-671 in the present study matched the ones published by ATCC and DSMZ respectively (Table 3) . 19 Previous STR analysis at ATCC revealed that the human GBM cell line SNB-19 had an identical profile to U373 MG, another GBM cell line, which led to SNB-19 being discontinued by ATCC. 20 As mentioned, our laboratory obtained the SNB-19 from the DSMZ, and this cell line was included in the DNA profiling study to determine whether our SNB-19 cell line had been crosscontaminated. Our data confirmed that the SNB-19 cell line in our cell bank was not cross-contaminated with U373 MG as reported by ATCC, based on the comparison between STR profiles of our SNB-19 cell line and the reported U373 MG (Table 3) . 21 According to the DSMZ data sheet, SNB-19 is a "subclone" of the human GBM cell line U251 MG. 22 This conclusion is supported by previous studies indicating that those 2 cell lines carry 96% genotype similarity and identical genomic variants, that is, tumor protein 53 (TP53), cyclin-dependent kinase inhibitor 2A (CDKN2A), and phosphatase and tensin homolog (PTEN) mutations, 16, 23 although SNB-19 and U251 MG have diverged at the karyotypical level. 24 Interestingly, when STR matching analysis was performed using DSMZ's online tool for the SNB-19 cell line included in the present study, the result showed that our SNB-19 had the identical STR profile to those for U251 MG and SNB-19 in the DSMZ database (Table 3) . Hence the SNB-19 cell line cultured in our laboratories has 100% genotype similarity to both cell lines (U251 MG and SNB-19) held at DSMZ. Our data also provide further evidence for the previous observation that SNB-19 is a derivative of U251 MG. In addition, the STR profiles of 3 commercial cell lines, NCI-H1299, SNB-19, and TE-671 obtained by capillary electrophoresis in our study were identical to those in published databases (Table 3) , indicating good reproducibility of the conventional method. In order to evaluate the reproducibility of this alternative electrophoresis platform in the application of STR FLA, 3 independent experiments were carried out with multiplex PCR amplification and fragment separation/sizing for the 10 cell lines in the DNA profiling study, using the same DNA sample of each cell line. Except for D5S818 in UP-016 and D21S11 in IN699 (shaded cells in Table 4 ), 98% (294/300) of the STR markers analyzed amongst 3 experiments showed a difference of +1-3 bp in their sizes, indicating an excellent reproducibility of the Bioanalyzer in FLA (Table 4) . Interestingly, fragment sizes revealed in experiment 3 were slightly larger in general for the majority of samples compared with those in experiments 1 and 2 (Table 4) , caused by slightly variable electrophoresis migration rates in those assays; however, due to the same trend of sizing differences demonstrated by all STR markers (instead of only 1 or 2 of them), the whole STR profile was maintained despite a slight shifting of the profile between different experiments. Hence, all cell lines showed highly identical DNA profiles from 3 independent experiments, as represented by IN699 and SNB-19 ( Fig. 2A and B) .
Consistent DNA Profiling of Cell Line Over Multiple Subcultures
Cross-contamination in cell culture invalidates research results and compromises the comparison between laboratories. To further validate the application of the microfluidic system in cell line DNA profiling and to detect possible cross-contamination during long-term cell culture, the same STR-based cell identity test was carried out with 5 genomic DNA samples collected from each of the 2 brain tumor cell lines, UP-029 and SEBTA-003, each with a 5-passage interval. As the data indicated, each cell line showed consistent STR profiles throughout 5 different passage numbers with +1-3 bp difference in sizing amongst 10 markers (Table 5A and B), suggesting that no cross-contamination occurred during the in vitro culture period and each cell line had maintained its unique DNA fingerprint. The overlaid DNA profiles of 5 different passages further 
An et al.: Brain tumor cell line authentication confirmed the identical STR fingerprints of the cells (Fig. 3A and B) . In accordance with the initial DNA profiling data, the sizing of all 10 markers in the cross-contamination test showed +1-3 bp difference amongst different passages (Table 5A and B) . Therefore, our data indicate that DNA profiling by microfluidic electrophoresis could be an effective approach to monitoring cross-contamination over time and subcultures. Notably, UP-029 was also included in the first part of this DNA fingerprinting study, where a different Agilent DNA 1000 Kit was used, and the profile of UP-029 cells maintained excellent similarity throughout different experiments/kits. These data provide further evidence for the reliability of this method and the Agilent assay kits in the application of cell line authentication. In addition, the StemElite ID System used in this study incorporates a sensitive mouse marker that can be detected after multiplex PCR should the sample contain genomic DNA from mouse; 
Discussion
The present study demonstrated a new application of the microfluidics-based electrophoresis method in STR-based DNA profiling of human cell lines, as shown here with brain tumor and brain tissue-related cell lines. In this study, the Agilent 2100 Bioanalyzer was used to analyze the STR fragments and was compared with the standard capillary electrophoresis method. Since its launch in 1999, the Bioanalyzer has been utilized for quality checks and quantification of DNA and RNA samples before downstream applications such as sequencing and microarray analyses. 11,25 -28 Due to its capacity to separate multiple DNA fragments within the same sample, it has been utilized in STR-based DNA genotyping of forensic samples. 13 The Agilent 2100 Bioanalyzer offers a broad range of prevalidated analysis kits, including the DNA 1000 chip that was used in this study. This DNA chip provides 5-25 bp sizing resolution for fragments of 100-500 bp. 17 The size range of the STR markers in the StemElite ID System is between 90 and 400 bp; 15 therefore it had been speculated that those amplified alleles would be separated on the DNA 1000 chip. Notably, the StemElite ID System is designed specifically for FLA by the Applied Biosystems capillary electrophoresis instruments, such as the ABI 3130 and 3130xl Genetic Analyzer. 15 Here our data demonstrate that this cell identification kit is valid for use with a microfluidic chip system, the Agilent 2100 Bioanalyzer. The STR profiles obtained from both FLA methods were highly comparable in this study, despite some discrepancies in the heterozygosity of several markers (Table 1 ; shaded cells). This could have been caused by unbalanced PCR amplification of those markers; that is, one allele was preferentially amplified over the other, and therefore the Bioanalyzer failed to detect the other allele due to low sample concentration, whereas the capillary electrophoresis system was able to capture the fluorescent signal and detect the labeled fragment. The multiplex PCR in this study was performed according to the manufacturer's protocol for the StemElite ID System, 15 but in future analyses, the amplification parameters could be modified in order to enhance balanced amplification of the markers and subsequently improve the resolution of this novel method in detecting heterozygous alleles. Notably, only 8% (8/100) of the total markers analyzed showed a discrepancy in heterozygosity between the new and conventional methods, and this had not affected the unique profile of each cell line studied (Table 1) .
In summary, the microfluidic system produced highly accurate and reproducible DNA profiling data from 10 different cell lines demonstrated in the present study, suggesting a new approach to cell line authentication using this platform. Furthermore, the comparison analysis featured by the Bioanalyzer 2100 Expert software allows a quick fingerprint check for different DNA samples from the same cell line by overlaying DNA profiles from either independent or the same DNA chip assays, as demonstrated in Figs 2 and 3. This analysis can also be performed for any 2 cell lines in order to compare and confirm their different profiles, as illustrated in Fig. 1C for TE-671 and UP-019, showing the distinct profile of each cell line. This could provide a reliable and cost-efficient downstream method for an STR-based cell line identity check in a cell culture laboratory.
It has been fully recognized that routine identity check should be conducted for human cell line cultures, and recently the importance of cell line verification prior to scientific publication has been reiterated by Anja Torsvik and colleagues, 29 as the authors discovered that the previously reported spontaneous transformation of human mesenchymal stem cells was in fact caused by cell line cross-contamination. Their report also sheds new light on the urgent need fora cell validation test of primary cell cultures for therapeutic purposes. 29 In the present study, the microfluidics-based method was employed to monitor possible cross-contamination over a long-term culture period, and excellent accuracy of this novel method was illustrated by the identical DNA profiles obtained from different passages of the same cell line (Table 5 and Fig. 3 ), indicating the potential of this method as a more effective alternative for a cross-contamination check. However, further studies need to be carried out to evaluate and compare the sensitivity and specificity of both FLA methods in terms of detecting cross-contamination, using carefully designed mixed cell cultures to represent the most common contamination scenarios.
Recently new standards for cell line authentication using STR fingerprinting have been proposed. 1 -5,30 It is critical that an internationally standardized STR panel be applied in the cell line identity test. The StemElite ID System employed in this study comprises 9 STR markers, which are in accordance with the markers utilized by ATCC and DSMZ, allowing comparison of the fingerprints of our NCI-H1299, SNB-19, and TE-671 cells with those in the larger databases. Notably, a recent study by Pierre Bady and colleagues 31 suggests that the commonly used similarity score of 0.8 is not sufficiently stringent to differentiate the origin of a cell line based on its DNA fingerprint consisting of only 9 STR loci, and it was proposed that either the number of STR markers measured should be expanded or additional cell line characteristics be included, such as specific mutations. The focus of this current study was to evaluate an alternative method for the standard FLA by capillary electrophoresis, which is time-consuming and costly for most laboratories. Both methods, however, are adaptable for expansion of STR markers. The DNA fingerprints of 3 commercially available cell lines recruited in the present study-NCI-H1299, SNB-19 and TE-671-demonstrated 100% similarity in comparison with the 9-marker fingerprint database of ATCC and DSMZ, confirming the origins of those cell lines held in our laboratories. The DNA profile of CC2565, another commercially available cell line analyzed in this study, was compared with the DSMZ database with no matching profile revealed (data not shown), indicating that the STR profile of CC2565 is not included in this database. Each of the 6 "in-house" cell lines presented in this study showed a unique DNA profile, suggesting that the 9-marker approach was sufficient to identify and differentiate those biopsy-derived cultures.
It is likely that there will be a need in the future to expand the panel of STR markers with an increasing number of "in-house" cell lines to be tested, and this method will accommodate this need. We have shown that this microfluidics-based electrophoresis platform could provide a more straightforward and cost-effective method for an STR-based cell line authentication test in our hands, compared with the standard capillary electrophoresis for DNA FLA. It is our hope that this novel application will promote an increase in the routine cell line validation test not only by cell bank repositories and distributors, but also by the research community. In addition, this method could be useful in a broader range of applications, such as testing human cancer cells directly An et al.: Brain tumor cell line authentication
